Cargando…

Spasticity in multiple sclerosis and role of glatiramer acetate treatment

INTRODUCTION: Spasticity is one of the most disabling and difficult-to-treat symptoms shown by patients with multiple sclerosis, who often show a suboptimal and unsatisfactory response to classic treatment and new available nonpharmacological alternatives. Due to the progressive nature of this condi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meca-Lallana, Jose Eustasio, Hernández-Clares, Rocío, Carreón-Guarnizo, Ester
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589813/ https://www.ncbi.nlm.nih.gov/pubmed/26445705 http://dx.doi.org/10.1002/brb3.367

Ejemplares similares

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
por: Sánchez-de la Rosa, Rainel, et al.
Publicado: (2015)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
por: Mirabella, Massimiliano, et al.
Publicado: (2022)

Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
por: de Oliveira, Tatiana de Melo Gomes, et al.
Publicado: (2008)

Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
por: Izquierdo, Guillermo, et al.
Publicado: (2015)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Glatiramer acetate desensitisation in multiple sclerosis patients - the case report
por: Novotna, Bronislava, et al.
Publicado: (2014)

Metabolic response to glatiramer acetate therapy in multiple sclerosis patients
por: De Riccardis, Lidia, et al.
Publicado: (2016)

Glatiramer in the treatment of multiple sclerosis
por: Rizvi, Syed A, et al.
Publicado: (2006)

Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients
por: Thamilarasan, Madhan, et al.
Publicado: (2013)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
por: Fernández, Oscar
Publicado: (2012)

Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis
por: Kuerten, Stefanie, et al.
Publicado: (2018)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis
por: Melnikov, Mikhail, et al.
Publicado: (2020)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
por: Caporro, Matteo, et al.
Publicado: (2014)

Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients
por: Zarzuelo-Romero, María José, et al.
Publicado: (2021)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing‐Remitting Multiple Sclerosis
por: Singhal, Tarun, et al.
Publicado: (2016)

Cognitive impairment in an animal model of multiple sclerosis and its amelioration by glatiramer acetate
por: Aharoni, Rina, et al.
Publicado: (2019)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: safety algorithm()
por: Valero-López, G., et al.
Publicado: (2020)

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
por: Waschbisch, Anne, et al.
Publicado: (2011)

Glatiramer Acetate Increases Phagocytic Activity of Human Monocytes In Vitro and in Multiple Sclerosis Patients
por: Pul, Refik, et al.
Publicado: (2012)

A case of Disseminated Herpes Zoster in a patient with Multiple Sclerosis on Glatiramer acetate
por: Halasan, C., et al.
Publicado: (2020)

Erratum to ‘‘Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm’’ [Neurologia. 2020;35(6):357–362]()
por: Valero-López, G., et al.
Publicado: (2020)

Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
por: Sanchez-de la Rosa, Rainel, et al.
Publicado: (2013)

Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis: A Case Report
por: Onmez, Attila, et al.
Publicado: (2013)

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use
por: Wynn, Daniel R.
Publicado: (2019)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021)

Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
por: Neuhaus, Oliver, et al.
Publicado: (2021)

Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate
por: Rojas-Morales, Emmanuel, et al.
Publicado: (2019)

Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines
por: Jongen, Peter Joseph, et al.
Publicado: (2016)

Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
por: Johnson, Kenneth P
Publicado: (2010)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
por: Honce, Justin M., et al.
Publicado: (2020)

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021)

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
por: Casanova, Ignacio, et al.
Publicado: (2023)

Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome
por: Kuzina, Ekaterina, et al.
Publicado: (2014)

Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report
por: Shirani, Afsaneh, et al.
Publicado: (2021)

Neuroprotective Effect of Glatiramer Acetate on Neurofilament Light Chain Leakage and Glutamate Excess in an Animal Model of Multiple Sclerosis
por: Aharoni, Rina, et al.
Publicado: (2021)

microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate
por: Dominguez-Mozo, María I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_orq9mavt4j0j76q47480ar03bk